257 related articles for article (PubMed ID: 1826699)
1. Immune dysfunction in mice with plasmacytomas. I. Evidence that transforming growth factor-beta contributes to the altered expression of activation receptors on host B lymphocytes.
Berg DJ; Lynch RG
J Immunol; 1991 Apr; 146(8):2865-72. PubMed ID: 1826699
[TBL] [Abstract][Full Text] [Related]
2. Expression, distribution and specificity of Fc receptors for IgM on murine B cells.
Mathur A; Lynch RG; Köhler G
J Immunol; 1988 Sep; 141(6):1855-62. PubMed ID: 2971716
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of interleukin 4-promoted CD23 production in human B lymphocytes by transforming growth factor-beta, interferons or anti-CD19 antibody is overriden on engaging CD40.
Gordon J; Katira A; Strain AJ; Gillis S
Eur J Immunol; 1991 Aug; 21(8):1917-22. PubMed ID: 1714394
[TBL] [Abstract][Full Text] [Related]
4. Leukotriene B4 potentiates the expression and release of Fc epsilon RII/CD23, and proliferation and differentiation of human B lymphocytes induced by IL-4.
Dugas B; Paul-Eugene N; Cairns J; Gordon J; Calenda A; Mencia-Huerta JM; Braquet P
J Immunol; 1990 Nov; 145(10):3406-11. PubMed ID: 2172383
[TBL] [Abstract][Full Text] [Related]
5. Efficiency of antigen presentation after antigen targeting to surface IgD, IgM, MHC, Fc gamma RII, and B220 molecules on murine splenic B cells.
Snider DP; Segal DM
J Immunol; 1989 Jul; 143(1):59-65. PubMed ID: 2471743
[TBL] [Abstract][Full Text] [Related]
6. Regulation of Fc receptor for IgE (CD23) and class II MHC antigen expression on Burkitt's lymphoma cell lines by human IL-4 and IFN-gamma.
Rousset F; Malefijt RW; Slierendregt B; Aubry JP; Bonnefoy JY; Defrance T; Banchereau J; de Vries JE
J Immunol; 1988 Apr; 140(8):2625-32. PubMed ID: 2965726
[TBL] [Abstract][Full Text] [Related]
7. Expression of B cell surface receptors. II. IL-4 can accelerate the developmental expression of the murine B cell IgE Fc receptor.
Waldschmidt TJ; Conrad DH; Lynch RG
J Immunol; 1989 Nov; 143(9):2820-7. PubMed ID: 2530279
[TBL] [Abstract][Full Text] [Related]
8. Increased T gamma and T mu cells in BALB/c mice with IgG and IgM plasmacytomas and hybridomas.
Mathur A; Lynch RG
J Immunol; 1986 Jan; 136(2):521-5. PubMed ID: 2934474
[TBL] [Abstract][Full Text] [Related]
9. Transforming growth factor-beta 1 is required for secretion of IgG of all subclasses by LPS-activated murine B cells in vitro.
Snapper CM; Waegell W; Beernink H; Dasch JR
J Immunol; 1993 Nov; 151(9):4625-36. PubMed ID: 8409423
[TBL] [Abstract][Full Text] [Related]
10. A combination of IL-10 and direct contact with plasma cell tumors decreases CD23 expression on splenic B cells.
Ruzek MC; Billadeau D; Mathur A
J Immunol; 1996 Mar; 156(6):2124-32. PubMed ID: 8690901
[TBL] [Abstract][Full Text] [Related]
11. Role of PAF and cytokines in the modulation of Fc epsilon RII/CD23 expression on human eosinophils.
Kawabe T; Maeda Y; Maekawa N; Tanaka M; Mayumi M; Mikawa H; Yodoi J
Adv Prostaglandin Thromboxane Leukot Res; 1991; 21B():989-95. PubMed ID: 1825444
[TBL] [Abstract][Full Text] [Related]
12. Low molecular weight B cell growth factor-responsive cloned human B cell lines. I. Phenotypic differences and lack of requirement for CD23 (Fc epsilon RII).
Warrington RJ; Rutherford WJ; Wong SK; Cook JM; Rector ES
J Immunol; 1989 Oct; 143(8):2546-52. PubMed ID: 2529311
[TBL] [Abstract][Full Text] [Related]
13. Altered response to and production of TGF-beta by B cells from autoimmune NZB mice.
Douglas RS; Woo EY; Capocasale RJ; Tarshis AD; Nowell PC; Moore JS
Cell Immunol; 1997 Aug; 179(2):126-37. PubMed ID: 9268496
[TBL] [Abstract][Full Text] [Related]
14. A phenotypically dominant regulatory mechanism suppresses major histocompatibility complex class II gene expression in a murine plasmacytoma.
Venkitaraman AR; Culbert EJ; Feldmann M
Eur J Immunol; 1987 Oct; 17(10):1441-6. PubMed ID: 3500056
[TBL] [Abstract][Full Text] [Related]
15. Induction of B cell activities by interleukin 4 is inhibited by a receptor-specific monoclonal antibody in vitro.
Maliszewski CR; Sato TA; Vanden Bos T; Beckmann MP; Grabstein KH
Eur J Immunol; 1990 Aug; 20(8):1735-40. PubMed ID: 2145164
[TBL] [Abstract][Full Text] [Related]
16. Control of B cell proliferation: arrest of B cells in late G1 underlies immunosuppression induced by plasma cell tumors.
Berman JE; Zolla-Pazner S
J Immunol; 1987 May; 138(9):2805-12. PubMed ID: 3494771
[TBL] [Abstract][Full Text] [Related]
17. B lymphocyte regulation of the immune system. II. Inhibition of Fc receptor expression of lymphocytes by BEF, a lymphokine of B cell origin.
del Guercio P; Zanetti M; del Guercio MF; Katz DH
J Immunol; 1985 Jun; 134(6):3926-33. PubMed ID: 3157754
[TBL] [Abstract][Full Text] [Related]
18. Cognate interactions between helper T cells and B cells. VI. TGF-beta inhibits B cell activation and antigen-specific, physical interactions between Th and B cells.
Bartlett WC; Purchio A; Fell HP; Noelle RJ
Lymphokine Cytokine Res; 1991 Jun; 10(3):177-83. PubMed ID: 1832051
[TBL] [Abstract][Full Text] [Related]
19. Soluble type II transforming growth factor-beta receptor inhibits established murine malignant mesothelioma tumor growth by augmenting host antitumor immunity.
Suzuki E; Kapoor V; Cheung HK; Ling LE; DeLong PA; Kaiser LR; Albelda SM
Clin Cancer Res; 2004 Sep; 10(17):5907-18. PubMed ID: 15355924
[TBL] [Abstract][Full Text] [Related]
20. Occupancy of CD72 (the CD5 counterstructure) enhances interleukin-4-dependent CD23 expression in resting B lymphocytes.
Katira A; Kamal M; Gordon J
Immunology; 1992 Jul; 76(3):422-6. PubMed ID: 1388135
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
